Pyoderma gangraenosum als diagnostische und therapeutische interdisziplinäre Herausforderung

Zusammenfassung

Das Pyoderma gangraenosum (PG) ist eine neutrophile Dermatose unklarer Genese, die sowohl in Assoziation zu hämatologischen und neoplastischen Systemerkrankungen, chronisch-entzündlichen Darmerkrankungen und autoinflammatorischen Syndromen als auch idiopathisch auftreten kann. Sowohl die Diagnosestellung wie auch die Therapie des PG stellen aufgrund seiner Seltenheit, des Fehlens großer randomisierter kontrollierter Studien und der unzureichend verstandenen Pathogenese eine Herausforderung in der klinischen Praxis dar. Diese Übersichtsarbeit beschreibt und diskutiert aktuelle Erkenntnisse, die das PG als autoinflammatorische Erkrankung beschreiben. Durch eine Dysregulation von T-Lymphozyten und myeloiden Zellen wie den neutrophilen Granulozyten kommt es zur Entstehung von Pusteln und großflächigen Ulzera. Klassische Therapieansätze umfassen eine anti-inflammatorische topische Therapie, eine Analgesie sowie die systemische Gabe von Immunmodulantien oder -suppressiva. Neuere, bisher nicht zugelassene Therapieoptionen sind der Einsatz von Biologika und JAK-Inhibitoren.

Abstract

Pyoderma gangrenosum (PG) is a neutrophilic dermatosis of unknown aetiology, which occurs idiopathically or in association with inflammatory bowel disease, haemato-oncological diseases and autoinflammatory syndromes. Both diagnosis and treatment of PG are challenging in clinical practice due to its rarity, lack of large randomised controlled trials and its poorly understood pathogenesis. This review discusses novel evidence regarding the pathophysiology of PG as an autoinflammatory disease and its treatment. Activation of the inflammasome, dysregulation of myeloid cells such as neutrophil granulocytes as well as T cells lead to the development of painful ulcerations. Traditional therapeutic approaches include anti-inflammatory topical therapy, analgesia and immunomodulatory or immunosuppressive drugs. Novel therapeutic options include biologics and JAK inhibitors, which are not yet approved.

Schlüsselwörter

Pyoderma gangraenosum - neutrophile Dermatose - chronische Wunde - Biologicals - Small-Molecular-Weight Inhibitoren

Key words

chronic ulceration - pyoderma gangrenosum - neutrophilic dermatosis - biologicals - small-molecular-weight inhibitorsonline publiziert 2022

^* Geteilte Erstautorenschaft

Publication History

Article published online:
25 May 2022

• Literatur

• 1 Brunsting L. Clinical and experimental observation in five cases occurring in adults. Arch Dermatol 1930; 22: 655-680
• 2 Langan SM, Groves RW, Card TR. et al. Incidence, mortality, and disease associations of pyoderma gangrenosum in the United Kingdom: a retrospective cohort study. Journal of Investigative Dermatology 2012; 132: 2166-2170
• 3 Rongisch R, Koll P, Eming S. Pyoderma gangraenosum: durch zielgerichtete Therapieansätze besser verstehen und behandeln können. Der Hautarzt 2020; 1-7
• 4 Shore RN. Pyoderma gangrenosum, defective neutrophil chemotaxis, and leukemia. Arch Dermatol 1976; 112: 1792-1793
• 5 Bedlow AJ, Davies EG, Moss AL. et al. Pyoderma gangrenosum in a child with congenital partial deficiency of leucocyte adherence glycoproteins. Br J Dermatol 1998; 139: 1064-1067 DOI: 10.1046/j.1365-2133.1998.02567.x.
• 6 Braswell SF, Kostopoulos TC, Ortega-Loayza AG. Pathophysiology of pyoderma gangrenosum (PG): an updated review. J Am Acad Dermatol 2015; 73: 691-698 DOI: 10.1016/j.jaad.2015.06.021.
• 7 Henry CM, Sullivan GP, Clancy DM. et al. Neutrophil-derived proteases escalate inflammation through activation of IL-36 family cytokines. Cell reports 2016; 14: 708-722
• 8 Takeuchi F, Streilein RD, Hall RP. Increased E-selectin, IL-8 and IL-10 gene expression in human skin after minimal trauma. Experimental dermatology 2003; 12: 777-783
• 9 Marzano AV, Damiani G, Ceccherini I. et al. Autoinflammation in pyoderma gangrenosum and its syndromic form (pyoderma gangrenosum, acne and suppurative hidradenitis). Br J Dermatol 2017; 176: 1588-1598 DOI: 10.1111/bjd.15226.
• 10 Marzano AV, Trevisan V, Gattorno M. et al. Pyogenic arthritis, pyoderma gangrenosum, acne, and hidradenitis suppurativa (PAPASH): a new autoinflammatory syndrome associated with a novel mutation of the PSTPIP1 gene. JAMA dermatology 2013; 149: 762-764
• 11 Lamkanfi M, Dixit VM. Mechanisms and functions of inflammasomes. Cell 2014; 157: 1013-1022 DOI: 10.1016/j.cell.2014.04.007.
• 12 Chokoeva AA, Cardoso JC, Wollina U. et al. Pyoderma gangrenosum – a novel approach?. Wien Med Wochenschr 2017; 167: 58-65 DOI: 10.1007/s10354-016-0472-z.
• 13 Brooklyn T, Williams A, Dunnill M. et al. T-cell receptor repertoire in pyoderma gangrenosum: evidence for clonal expansions and trafficking. British Journal of Dermatology 2007; 157: 960-966
• 14 Maverakis E, Marzano AV, Le ST. et al. Pyoderma gangrenosum. Nat Rev Dis Primers 2020; 6: 81 DOI: 10.1038/s41572-020-0213-x.
• 15 Marzano AV, Cugno M, Trevisan V. et al. Role of inflammatory cells, cytokines and matrix metalloproteinases in neutrophil-mediated skin diseases. Clin Exp Immunol 2010; 162: 100-107 DOI: 10.1111/j.1365-2249.2010.04201.x.
• 16 Marzano AV, Fanoni D, Antiga E. et al. Expression of cytokines, chemokines and other effector molecules in two prototypic autoinflammatory skin diseases, pyoderma gangrenosum and Sweet’s syndrome. Clin Exp Immunol 2014; 178: 48-56 DOI: 10.1111/cei.12394.
• 17 Perry HO, Winkelmann RK. Bullous pyoderma gangrenosum and leukemia. Archives of Dermatology 1972; 106: 901-905
• 18 O’Loughlin S, Perry HO. A diffuse pustular eruption associated with ulcerative colitis. Archives of dermatology 1978; 114: 1061-1064
• 19 Wilson-Jones E, Winkelmann R. Superficial granulomatous pyoderma: a localized vegetative form of pyoderma gangrenosum. Journal of the American Academy of Dermatology 1988; 18: 511-521
• 20 Hughes AP, Jackson JM, Callen JP. Clinical features and treatment of peristomal pyoderma gangrenosum. Jama 2000; 284: 1546-1548
• 21 Tolkachjov SN, Fahy AS, Wetter DA. et al. Postoperative pyoderma gangrenosum (PG): the Mayo Clinic experience of 20 years from 1994 through 2014. J Am Acad Dermatol 2015; 73: 615-622 DOI: 10.1016/j.jaad.2015.06.054.
• 22 Jockenhöfer F, Wollina U, Salva KA. et al. The PARACELSUS score: a novel diagnostic tool for pyoderma gangrenosum. Br J Dermatol 2019; 180: 615-620 DOI: 10.1111/bjd.16401.
• 23 Maverakis E, Ma C, Shinkai K. et al. Diagnostic Criteria of Ulcerative Pyoderma Gangrenosum: A Delphi Consensus of International Experts. JAMA Dermatol 2018; 154: 461-466 DOI: 10.1001/jamadermatol.2017.5980.
• 24 Weber N, Schaer D, Vallelian F. Behçet disease. Praxis (Bern 1994) 2013; 102: 1445-1453 DOI: 10.1024/1661-8157/a001510.
• 25 Kridin K, Cohen AD, Amber KT. Underlying systemic diseases in pyoderma gangrenosum: a systematic review and meta-analysis. American journal of clinical dermatology 2018; 19: 479-487
• 26 POWELL FC, SCHROETER AL, SU WPD. et al. Pyoderma Gangrenosum: A Review of 86 Patients. QJM: An International Journal of Medicine 1985; 55: 173-186 DOI: 10.1093/oxfordjournals.qjmed.a067865.
• 27 Reichrath J, Bens G, Bonowitz A. et al. Treatment recommendations for pyoderma gangrenosum: an evidence-based review of the literature based on more than 350 patients. J Am Acad Dermatol 2005; 53: 273-283 DOI: 10.1016/j.jaad.2004.10.006.
• 28 Ormerod AD, Thomas KS, Craig FE. et al. Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial. BMJ 2015; 350: h2958 DOI: 10.1136/bmj.h2958.
• 29 Brooklyn TN, Dunnill MG, Shetty A. et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut 2006; 55: 505-509 DOI: 10.1136/gut.2005.074815.
• 30 von den Driesch P. Pyoderma gangrenosum: a report of 44 cases with follow-up. Br J Dermatol 1997; 137: 1000-1005
• 31 Hasselmann DO, Bens G, Tilgen W. et al. Pyoderma gangrenosum: clinical presentation and outcome in 18 cases and review of the literature. J Dtsch Dermatol Ges 2007; 5: 560-564 DOI: 10.1111/j.1610-0387.2007.0328.x.
• 32 Kontochristopoulos GJ, Stavropoulos PG, Gregoriou S. et al. Treatment of pyoderma gangrenosum with low-dose colchicine. Dermatology 2004; 209: 233-236
• 33 Arguelles-Arias F, Castro-Laria L, Lobaton T. et al. Characteristics and treatment of pyoderma gangrenosum in inflammatory bowel disease. Dig Dis Sci 2013; 58: 2949-2954 DOI: 10.1007/s10620-013-2762-2.
• 34 Suarez-Perez JA, Herrera-Acosta E, Lopez-Navarro N. et al. Pyoderma gangrenosum: a report of 15 cases and review of the literature. Actas Dermosifiliogr 2012; 103: 120-126 DOI: 10.1016/j.ad.2011.04.010.
• 35 Hurabielle C, Schneider P, Baudry C. et al. Certolizumab pegol – A new therapeutic option for refractory disseminated pyoderma gangrenosum associated with Crohn’s disease. Journal of Dermatological Treatment 2016; 27: 67-69
• 36 Guenova E, Teske A, Fehrenbacher B. et al. Interleukin 23 expression in pyoderma gangrenosum and targeted therapy with ustekinumab. Arch Dermatol 2011; 147: 1203-1205 DOI: 10.1001/archdermatol.2011.168.
• 37 Benzaquen M, Monnier J, Beaussault Y. et al. Pyoderma gangrenosum arising during treatment of psoriasis with adalimumab: Effectiveness of ustekinumab. Australas J Dermatol 2017; 58: e270-e271 DOI: 10.1111/ajd.12545.
• 38 Goldminz AM, Botto NC, Gottlieb AB. Severely recalcitrant pyoderma gangrenosum successfully treated with ustekinumab. J Am Acad Dermatol 2012; 67: e237-e238 DOI: 10.1016/j.jaad.2012.04.045.
• 39 John JM, Sinclair RD. Tildrakizumab for treatment of refractory pyoderma gangrenosum of the penis and polymyalgia rheumatica: Killing two birds with one stone. Australas J Dermatol 2020; 61: 170-171 DOI: 10.1111/ajd.13196.
• 40 Burgdorf B, Schlott S, Ivanov IH. et al. Successful treatment of a refractory pyoderma gangrenosum with risankizumab. Int Wound J 2020; 17: 1086-1088 DOI: 10.1111/iwj.13359.
• 41 Prada Lobato J, Moreno García M, Madrid González M. Secukinumab en pioderma gangrenoso: descripción de un caso. Medicina Clínica 2019; 152: 246-246
• 42 Kolios AG, Maul JT, Meier B. et al. Canakinumab in adults with steroid-refractory pyoderma gangrenosum. Br J Dermatol 2015; 173: 1216-1223 DOI: 10.1111/bjd.14037.
• 43 Beynon C, Chin MF, Hunasehally P. et al. Successful Treatment of Autoimmune Disease-Associated Pyoderma Gangrenosum With the IL-1 Receptor Antagonist Anakinra: A Case Series of 3 Patients. J Clin Rheumatol 2017; 23: 181-183 DOI: 10.1097/RHU.0000000000000511.
• 44 Fenini G, Contassot E, French LE. Potential of IL-1, IL-18 and Inflammasome Inhibition for the Treatment of Inflammatory Skin Diseases. Front Pharmacol 2017; 8: 278 DOI: 10.3389/fphar.2017.00278.
• 45 Braun-Falco M, Kovnerystyy O, Lohse P. et al. Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH) – a new autoinflammatory syndrome distinct from PAPA syndrome. J Am Acad Dermatol 2012; 66: 409-415 DOI: 10.1016/j.jaad.2010.12.025.
• 46 Lu JD, Milakovic M, Ortega-Loayza AG. et al. Pyoderma gangrenosum: proposed pathogenesis and current use of biologics with an emphasis on complement C5a inhibitor IFX-1. Expert Opin Investig Drugs 2020; 29: 1179-1185 DOI: 10.1080/13543784.2020.1819981.
• 47 Kochar B, Herfarth N, Mamie C. et al. Tofacitinib for the treatment of pyoderma gangrenosum. Clinical Gastroenterology and Hepatology 2019; 17: 991-993
• 48 Reinders P, Otten M, Augustin M. et al. Anwendungsbereiche der Teledermatologie. Der Hautarzt 2022; 73: 47-52 DOI: 10.1007/s00105-021-04917-y.